A
Avrobio
Clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease
About Avrobio
AVROBIO, Inc. is a clinical-stage gene therapy company focused on developing transformative therapies to treat rare genetic diseases. The company operates in the biotechnology sector, targeting conditions such as Gaucher disease and Cystinosis. AVROBIO's business model revolves around advancing its proprietary gene therapy platform through clinical trials, with the goal of achieving regulatory approval and commercializing its therapies. Revenue is primarily generated through funding, partnerships, and potential future sales of approved therapies. The company serves patients with rare genetic disorders, aiming to provide them with long-term relief and improved quality of life. AVROBIO's market includes healthcare providers, patients, and research institutions. The company leverages its extensive experience in gene therapy science and strategic partnerships to navigate the complex landscape of clinical development and regulatory approval.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2015
- Headquarters
- Cambridge, United States
- Employees
- 16
- Open positions
- None listed
- Dealroom signal
- 63.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Jan 2024 | $0 | — | Tectonic Therapeutic | ↗ |
| IPOOther financing | Jun 2018 | $0 | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Avrobio is 1.1K monthly website visits, down 73.2% over the last three months. Avrobio's team declined 69.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A6 investors entered at this stage
SV Health Investors
Clarus Ventures
Citadel
Cormorant Asset Management
Aisling Capital
5Y Capital
Other known investors3 additional known investors
Tectonic Therapeutic
University Health Network
Brace Pharma
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Avrobio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Avrobio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.